Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 24, Issue 1, 2011, Pages 49-55

  Chung, Y ^a   Law, S ^a   Kwong, D L W ^b   Luk, J M ^c  

^a Division of Esophageal and Upper Gastrointestinal Surgery   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Enzyme linked immunosorbent assay; Esophageal squamous cell carcinoma; Neoadjuvant chemoradiation therapy; Soluble E cadherin

Indexed keywords

SOLUBLE E CADHERIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; CADHERINS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551584719     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2010.01093.x     Document Type: Article

References (40)

1. Lam K Y, Ma L. Pathology of esophageal cancers: local experience and current insights. Chin Med J (Engl) 1997; 110: 459-64.
2. Lam A K. Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol 2000; 33: 71-90.
3. Vestweber D, Kemler R. Some structural and functional aspects of the cell adhesion molecule uvomorulin. Cell Differ 1984; 15: 269-73.
4. Chung Y, Lam A K, Luk J M et al. Altered E-cadherin expression and p120 catenin localization in esophageal squamous cell carcinoma. Ann Surg Oncol 2007; 14: 3260-7.
5. Jawhari A U, Noda M, Farthing M J et al. Abnormal expression and function of the E-cadherin-catenin complex in gastric carcinoma cell lines. Br J Cancer 1999; 80: 322-30.
6. Chan A O, Wong B C, Lan H Y et al. Deregulation of E-cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. J Gastroenterol Hepatol 2003; 18: 534-9.
7. Valizadeh A, Karayiannakis A J, El-Hariry I et al. Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps. Am J Pathol 1997; 150: 1977-84.
8. Ghadimi B M, Behrens J, Hoffmann I et al. Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. Eur J Cancer 1999; 35: 60-5.
9. Sarrio D, Perez-Mies B, Hardisson D et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004; 23: 3272-83.
10. Nakopoulou L, Zervas A, Gakiopoulou-Givalou H et al. Prognostic value of E-cadherin, beta-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res 2000; 20: 4571-8.
11. Katayama M, Hirai S, Kamihagi K et al. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 1994; 69: 580-5.
12. Griffiths T R, Brotherick I, Bishop R I et al. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 1996; 74: 579-84.
13. Gofuku J, Shiozaki H, Doki Y et al. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer 1998; 78: 1095-101.
14. Billion K, Ibrahim H, Mauch C et al. Increased soluble E-cadherin in melanoma patients. Skin Pharmacol Physiol 2006; 19: 65-70.
15. Kuefer R, Hofer M D, Zorn C S et al. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer 2005; 92: 2018-23.
16. Wilmanns C, Grossmann J, Steinhauer S et al. Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients. Clin Exp Metastasis 2004; 21: 75-8.
17. Noe V, Fingleton B, Jacobs K et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114: 111-18.
18. Lochter A, Galosy S, Muschler J et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997; 139: 1861-72.
19. Nawrocki-Raby B, Gilles C, Polette M et al. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 2003; 105: 790-5.
20. Kuefer R, Hofer M D, Gschwend J E et al. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 2003; 9: 6447-52.
21. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993; 5: 806-11.
22. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994; 1198: 11-26.
23. Chan A O, Chu K M, Lam S K et al. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer 2005; 104: 740-6.
24. Adachi Y, Oshiro T, Mori M et al. Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol 1997; 4: 137-40.
25. Chan A O, Lam S K, Chu K M et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001; 48: 808-11.
26. Chan A O, Chu K M, Lam S K et al. Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol 2003; 21: 2288-93.
27. Greene L F, Page D L, Fleming I D et al. AJCC Cancer Staging Manual/American Joint Committee on Cancer. New York: Springer, 2002; 91-5.
28. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-5.
29. Inada S, Koto T, Futami K et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 1999; 29: 493-503.
30. Nair K S, Naidoo R, Chetty R. Microsatellite analysis of the APC gene and immunoexpression of E-cadherin, catenin, and tubulin in esophageal squamous cell carcinoma. Hum Pathol 2006; 37: 125-34.
31. Sato F, Shimada Y, Watanabe G et al. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 1999; 80: 1366-72.
32. Gadducci A, Ferdeghini M, Cosio S et al. Preoperative serum E-cadherin assay in patients with ovarian carcinoma. Anticancer Res 1999; 19: 769-72.
33. Berx G, Becker K F, Hofler H et al. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998; 12: 226-37.
34. Si H X, Tsao S W, Lam K Y et al. E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett 2001; 173: 71-8.
35. Ireton R C, Davis M A, van H J et al. A novel role for p120 catenin in E-cadherin function. J Cell Biol 2002; 159: 465-76.
36. Fuchs M, Hermannstadter C, Hutzler P et al. Deletion of exon 8 increases cisplatin-induced E-cadherin cleavage. Exp Cell Res 2007.
37. Dolle L, Oliveira M J, Bruyneel E et al. Nerve growth factor mediates its pro-invasive effect in parallel with the release of a soluble E-cadherin fragment from breast cancer MCF-7/AZ cells. J Dairy Res 2005; 72: 20-6.
38. Hayashido Y, Hamana T, Yoshioka Y et al. Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin. Int J Oncol 2005; 27: 693-8.
39. Bellovin D I, Bates R C, Muzikansky A et al. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005; 65: 10938-45.
40. Urschel J D, Vasan H, Blewett C J. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183: 274-9.